Factors affecting treatment outcome in patients with idiopathic nonspecific interstitial pneumonia: a nationwide cohort study by �씠�긽�썕 et al.
RESEARCH Open Access
Factors affecting treatment outcome in
patients with idiopathic nonspecific
interstitial pneumonia: a nationwide
cohort study
Sang Hoon Lee1,2, Moo Suk Park3, Song Yee Kim3, Dong Soon Kim4, Young Whan Kim5, Man Pyo Chung6,
Soo Taek Uh7, Choon Sik Park8, Sung Woo Park8, Sung Hwan Jeong9, Yong Bum Park10, Hong Lyeol Lee11,
Jong Wook Shin12, Eun Joo Lee13, Jin Hwa Lee14, Yangin Jegal15, Hyun Kyung Lee16, Yong Hyun Kim17,
Jin Woo Song4 and Jong Sun Park1*
Abstract
Background: The effects of corticosteroid-based therapy in patients with idiopathic nonspecific interstitial
pneumonia (iNSIP), and factors affecting treatment outcome, are not fully understood. We aimed to investigate the
long-term treatment response and factors affecting the treatment outcome in iNSIP patients from a multi-center
study in Korea.
Methods: The Korean interstitial lung disease (ILD) Study Group surveyed ILD patients from 2003 to 2007. Patients
were divided into two groups to compare the treatment response: response group (forced vital capacity (FVC)
improves ≥10% after 1 year) and non-response group (FVC <10%). Factors affecting treatment response were
evaluated by multivariate logistic regression analysis.
Results: A total of 261 patients with iNSIP were enrolled, and 95 patients were followed-up for more than 1 year.
Corticosteroid treatment was performed in 86 patients. The treatment group showed a significant improvement in
lung function after 1-year: FVC, 10.0%; forced expiratory volume (FEV1), 9.8%; diffusing capacity of the lung for
carbon monoxide (DLco), 8.4% (p < 0.001). Sero-negative anti-nuclear antibody (ANA) was significantly related with
lung function improvement. Sero-positivity ANA was significantly lower in the response group (p = 0.013),
compared to that in the non-response group. A shorter duration of respiratory symptoms at diagnosis was
significantly associated with a good response to treatment (p = 0.018).
Conclusion: Treatment with corticosteroids and/or immunosuppressants improved lung function in iNSIP patients,
which was more pronounced in sero-negative ANA and shorter symptom duration patients. These findings suggest
that early treatment should be considered in iNSIP patients, even in an early disease stage.
Keywords: Non-specific interstitial pneumonia, Treatment, Pulmonary lung function
* Correspondence: jspark.im@gmail.com
1Department of Internal Medicine, Division of Pulmonary and Critical Care
Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro, 173
Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lee et al. Respiratory Research  (2017) 18:204 
DOI 10.1186/s12931-017-0686-7
Background
Non-specific interstitial pneumonia (NSIP) is a type of
interstitial idiopathic interstitial pneumonia (IIP) mainly
affecting female non-smokers aged 40–60 years. Al-
though more rigorous studies are needed, the prevalence
of idiopathic NSIP (iNSIP) is estimated to be between 1
and 9 in 100,000 [1, 2]. NSIP can present as idiopathic
or is associated with secondary conditions, such as con-
nective tissue disease (CTD), human immunodeficiency
virus infection, IgG4-related disease, bone marrow trans-
plant, or toxin/drug-related conditions [2–4]. In addition,
NSIP with connective tissue disease has recently been re-
classified as interstitial pneumonia with autoimmune
disease [5].
Although the natural course of iNSIP is not yet
known, previous studies showed that the prognosis of
NSIP is favorable when compared with idiopathic
pulmonary fibrosis (IPF) [6–8]. Corticosteroid and im-
munosuppressive agents (including azathioprine, cyclo-
phosphamide, cyclosporine, and mycophenolate mofetil)
are widely used and thought to be beneficial for patients
with NSIP [3, 9, 10]. However, changes to pulmonary
function are not fully understood in both untreated and
treated NSIP patients, especially in patients with low
severity NSIP. Additionally, previous studies have
addressed the risk factors and medical conditions associ-
ated with mortality rate, relapse, and progression of the
disease, but the degree of response and factors affecting
treatment have not been well studied [10, 11].
The Korean Interstitial Lung Disease (ILD) Research
Group performed a nationwide survey to investigate the
characteristics of patients with ILD, including iNSIP. In
the present multicenter, nationwide study, we aimed to
investigate the effect of treatment and the factors affect-
ing the treatment outcome in patients with surgically
proven-iNSIP.
Methods
Study population
Figure 1 shows the patient-flow chart. In total, 2186
idiopathic interstitial pneumonias (IIP) patients were
registered by the Korean ILD Research Group, which in-
cludes pulmonologists from 54 University hospitals
across the country with more than 500 beds starting
2006, from January 1, 2003, to December 31, 2007.
Patients with a history of using medication that could
provoke ILD (e.g., amiodarone or cytotoxic agent), and
had a collagen-vascular disease were excluded from the
study. In addition, patients with granulomatous diffuse
parenchymal lung disease (e.g., sarcoidosis) or a rare
form of ILD (e.g., lymphangioleiomyomatosis or
pulmonary Langerhans cell histocytosis) were initially
excluded from the study. NSIP was diagnosed based on
the American Thoracic Society/European Respiratory
Society (ATS/ERS) 2002 guidelines via a multidisciplin-
ary approach by a pulmonologist, a chest specific radi-
ologist, and pathologists [12]. Patients diagnosed with
IIP other than NSIP, including acute interstitial pneumo-
nia, cryptogenic organizing pneumonia, desquamative
interstitial pneumonia, lymphocytic interstitial pneumo-
nia, nonspecific interstitial pneumonia, and respiratory
bronchiolitis-associated interstitial lung disease, were ex-
cluded. Patients diagnosed clinically without a surgical
lung biopsy were excluded. Additionally, patients for
whom definitive diagnoses could not be made at each
hospital, were reviewed by the Scientific Committee of
the Korean Academy of Tuberculosis and Respiratory
Diseases. Among the 261 patients with NSIP, those who
developed a new CTD (n = 9) were excluded. Patients
with hypersensitivity pneumonitis (HP), as indicated by
the patient’s history, clinical symptoms, and serologic
test results, were also excluded from the study. Finally,
252 patients with iNSIP were analyzed in this study; 157
patients were followed-up within 1 year, and 95 patients
were followed-up after >1 year. Clinical (age, gender,
smoking status, smoking amount, respiratory symptom,
comorbidity, and outcome), physiological (pulmonary
function test [PFT]), and laboratory (arterial blood gas
analysis, C-reactive protein, anti-nuclear antibody
[ANA], and rheumatoid factor) findings were retrospect-
ively investigated. All patients’ data were recorded in a
web-based registry (www.ild.or.kr).
The 95 patients who were followed-up after >1 year
were divided into two groups: a no treatment group
(n = 9) and a treatment group (n = 86). Patients who
were prescribed corticosteroid or immunosuppressive
agents were defined as “treatment group”. The mean
duration of treatment was 11.8 ± 8.3 months. The no
treatment group patients were either only prescribed
medication for symptom control or no medication at all.
To determine the effect of the treatment, the treat-
ment group was further divided into two sub-groups.
The response group was defined as patients with a
change of ≥10% between the initial predicted forced vital
capacity (FVC) (%) and the 1-year follow-up predicted
FVC (%). The non-response group was defined as
patients with a change of <10% between the initial
predicted FVC (%) and the 1-year follow-up predicted
FVC (%).
Statistical analysis
Continuous variables were expressed as the mean ±
standard deviation (SD) or median with interquartile
range and compared by Student’s t-test or a Mann
Whitney U-test according to the distribution of patients.
Categorical variables were presented as frequency (n)
and percentage (%), and were analyzed by Fisher’s exact
test or Pearson’s chi-square test. A Wilcoxon signed
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rank test or Paired t-test were conducted to compare the
effect of treatment (initial PFT results vs 1-year follow-
up results). A repeated measures ANOVA was
conducted to compare the change in lung function
between the response group and non-response group at
1 year. A logistic regression model was used to investi-
gate the factors affecting the treatment outcome. An
adjusted p value <0.05 was considered to indicate signifi-
cance. SPSS™ Version 22.0 (SPSS, Chicago, Illinois,
USA), was used for all statistics analysis.
Results
Among 252 patients with iNSIP, 95 patients who were
followed-up for over 1 year were analyzed to evaluate
treatment response in this study. Table 1 shows the
characteristics of the patients with iNSIP. The mean age
was 57.1 ± 10.7 years, and females (65.1%) were predom-
inant. The mean follow-up duration was 21.6 ±
16.6 months among all patients, and 32.1 ± 13.9 months
in patients followed-up after >1 year. Overall lung func-
tion was slightly decreased compared to normal; FVC
(%) was 71.8 ± 18.4, forced expiratory volume (FEV1) (%)
was 79.8 ± 20.9, and diffusing capacity of the lung for
carbon monoxide (DLCO) (%) was 64.9 ± 21.3. Most of
the patients were not smokers. Dyspnea (77.8%) and
cough (72.6%) were the most common respiratory
symptoms.
Clinical, physiologic, and laboratory data for the no
treatment group and treatment group are shown in
Table 2. More than 95% of patients were treated with
steroid (Additional file 1: Table S1). In the treatment
group, the median age was lower than that in the treat-
ment group, although the difference was not significant
(p = 0.061). Gender, follow-up duration, PFT results,
smoking, initial respiratory symptoms, laboratory results,
and comorbidities did not differ significantly between
the groups (Table 2 and Additional file 1: Table S2). The
change in lung function between the initial visit and the
1-year follow-up was investigated (Additional file 1:
Table S3). In the no treatment group, although the FVC
(%), FEV1 (%), and DLCO (%) were increased 1 year after
diagnosis, compared to the initial assessment, these
changes in PFT were not significant (p = 0.276, p = 0.400,
and p = 0.489, respectively). However, in the treatment
group, these values were all significantly improved after
1 year (p < 0.001, all).
Fig. 1 Flow chart of the study population. Initially, 2186 patients with interstitial lung disease (ILD) were enrolled by the Korean study group
between January 1, 2003, and December 31, 2007. A total of 261 surgically diagnosed patients with non-specific interstitial pneumonia (NSIP)
were analyzed in this study; 1925 patients with a different diagnosis other than NSIP were excluded from this study. One hundred and fifty seven
patients were followed-up within 1 year, and 95 patients were followed-up after >1 year. Of these 95 patients, nine were in the conservative care
group, and 86 in the treatment group. The treatment group was defined as those prescribed corticosteroid and/or immunosuppressant therapy,
and conservative care group was defined as those who were only prescribed medication for symptom control. IPF: idiopathic pulmonary fibrosis,
COP: cryptogenic organizing pneumonia, AIP: acute interstitial pneumonia, DIP: desquamative interstitial pneumonia, RB-ILD: respiratory
bronchiolitis-associated interstitial lung disease, LIP: lymphocytic interstitial pneumonia
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Table 3 also shows the difference in lung function be-
tween the initial PFT and 1-year follow-up PFT per the
sero-positivity of ANA. The ANA results were available
in 59 patients (62.1%). Forty-one patients (69.5%) with
an initial negative ANA showed a significant improve-
ment in lung function after 1 year; FVC (%) increased
by 11.1%, FEV1 (%) by 11.3%, and DLCO (%) by 12.1%
(p = 0.008, p = 0.005, and p < 0.001, respectively). How-
ever, sero-positive patients did not show a significant
improvement in lung function after 1-year.
We compared the baseline characteristics between the
response group and non-response groups (Table 4). Age
and composition proportion of gender were similar
between the groups (p = 0.895 and p = 0.705). In the re-
sponse group, the follow-up duration was significantly
longer than in the non-response group (p = 0.006), but
the duration of respiratory symptoms was shorter (3.4 ±
4.4 months vs 7.1 ± 9.3 months, respectively; p = 0.038).
With regard to pulmonary function, initial FVC (%),
FEV1 (%), and DLCO (%) were significant higher in
the non-response group than in the response group
(p < 0.001, p < 0.001, and p = 0.008, respectively).
Current smokers were only found in the non-
response group (p = 0.022). There were no significant
differences in the initial respiratory symptoms, labora-
tory results, and comorbidities between the two
groups (Table 4 and Additional file 1: Table S2).
However, the proportion of ANA sero-positivity was
higher in the non-response group than in the response
group (p = 0.013). Furthermore, in the non-response
group, two patients (4.5%) died during the follow-up
period. Figure 2 shows the change in pulmonary lung
function over time (initial, 6 month, and 12 month) be-
tween the two groups. The FVC improved by 24.6%, and
DLCO improved by 20.2% after 1 year in the response
group. However, in the non-response group, lung function
after 1 year did not differ greatly from baseline. Therefore,
there were significant differences in FVC and DLCO be-
tween the two groups over time (p < 0.001, and p = 0.002).
Multivariate analysis with logistic regression was
conducted to investigate the risk factors for the non-
response group (Table 5). Age, gender, duration of
respiratory symptoms, FVC (%), DLCO (%), and arterial
oxygen tension (PaO2) were examined. Although ANA
showed a significant difference between the response
group and non-response group, only 15 patients showed
positivity (Table 4). Thus, ANA was excluded from the
multivariate analysis. The duration of symptoms at diag-
nosis was significantly associated with the response to
treatment (hazard ratio (HR), 1.385; 95% CI, 1.058–
1.813; p = 0.018). In addition, to identify the factors
related to treatment failure, we defined patients with at
least a 5% reduction in lung function reduction as “treat-
ment failure” and performed logistic analysis. Thus, we
found that age was significantly related to treatment
failure. Older patients showed a tendency to experience
treatment failure (Additional file 1: Table S4).
Discussion
Although the prognosis of iNSIP is better than that of
IPF, the 5-year mortality rate is estimated to be 17.7%
[2]. To this date, there is no generally accepted guideline
for the treatment of iNSIP; however, a previous study
showed that corticosteroid and/or immunosuppressant
therapy helped in maintaining or improving lung func-
tion in 81% patients with iNSIP [9]. Our study showed
that the serologic negativity of ANA was related with an
Table 1 Characteristics of the study population
Total patients
(n = 261)
Patients followed up
more than 1 year (n = 95)
Age (year) 57.1 ± 10.7 56.2 ± 10.3
F: M 170 (65.1): 91 (34.9) 64 (67.4): 31 (32.6)
*Follow-up duration
(month)
21.6 ± 16.6 32.1 ± 13.9
Pulmonary function test
FVC (%) 71.8 ± 18.4 72.5 ± 19.3
FEV1 (%) 79.8 ± 20.9 81.1 ± 21.2
DLco (%) 64.9 ± 21.3 64.7 ± 22.5
*Resting PaO2 mm Hg 81.6 ± 17.3 86.7 ± 14.8
Smoking status
Never smoker 169/241 (70.1) 68/92 (73.9)
Ex-smoker 38/241 (15.8) 16/92 (17.4)
current smoker 34/241 (14.1) 8/92 (8.7)
*Smoking amount (Pys) 29.3 ± 16.8 29.0 ± 15.2
Initial symptom
Dyspnea of exertion 179/230 (77.8) 64/80 (80.0)
Cough 159/219 (72.6) 55/81 (67.9)
Sputum 69/186 (37.1) 28/71 (39.4)
*Duration of symptom
(month)
6.2 ± 10.2 7.1 ± 12.0
*CRP (mg/dL) 2.52 ± 6.21 1.56 ± 3.68
ANA (positive) 58/185 (31.4) 18/59 (30.5)
RF (positive) 28/173 (16.2) 11/59 (18.6)
Outcome
Alive 157/261 (60.2) 73/95 (76.8)
Death 26/261 (10.0) 3/95 (3.2)
Follow-up loss 78/261 (29.9) 19/95 (20.0)
Note: Values in parentheses are percentages
F:M female:male, FVC, forced vital capacity, % pred percentage of the predicted
value, FEV1 forced expiratory volume, DLCO diffusing capacity of the lung for
carbon monoxide, PaO2 arterial oxygen tension, CRP C-reactive protein,
ANA antinuclear antibody, RF rheumatoid factor
*Follow-up duration, smoking amount, duration of symptoms, and CRP
showed a non-normal distribution in all patients
*Resting PaO2 mm Hg, duration of symptom, and CRP showed a non-normal
distribution in patients followed up for more than 1 year
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improvement in pulmonary function, and patients who
had a relatively shorter duration of initial respiratory
symptoms responded to corticosteroids better than
iNSIP patients with a longer duration of initial respira-
tory symptoms.
Since Bjoraker et al. [13] reported the importance of
the differentiation of NSIP from IPF, there has been
much progression in the diagnosis of NSIP as a formally
approved disease entity, but there are still no clear
guidelines for diagnosis and treatment [2, 5, 12, 14].
Furthermore, some medical conditions (CTD-related
ILD, hypersensitivity pneumonitis, cryptogenic organiz-
ing pneumonia, infection, or drug-induced lung disease)
are related with NSIP, and therefore, the histologic
Table 2 Characteristics according to treatment in patients followed-up for more than one year
No treatment group (n = 9) Treatment group (n = 86) P-value
Age (year) 63.0 (57.5, 66.0) 55.0 (48.0, 64.3) 0.061
F: M 5 (55.6): 4 (44.4) 59 (68.6): 27 (31.4) 0.467
Follow-up duration (month) 23.0 (20.5, 43.0) 30.5 (20.8, 42.0) 0.412
Pulmonary function test
FVC (%) 83.0 (63.5, 91.0) 69.5 (58.0, 87.0) 0.291
FEV1 (%) 100.0 (75.0, 104.5) 80.0 (64.0, 95.0) 0.111
DLco (%) 70.5 (61.3, 79.3) 48.0 (61.0, 80.0) 0.165
*Resting PaO2 mm Hg 85.0 (76.3, 91.0) 89.0 (77.5, 98.0) 0.442
Smoking status 0.302
Never smoker 6/9 (66.7) 62/83 (74.7)
Ex-smoker 1/9 (11.1) 15/83 (18.1)
current smoker 2/9 (22.2) 6/83 (7.2)
Smoking amount (Pys) 30.0 (15.0, −) 30.0 (17.5, 44.0) 0.539
Initial symptom
Dyspnea of exertion 6/9 (66.7) 58/71 (81.7) 0.373
Cough 6/9 (66.7) 49/72 (68.1) 1.000
Sputum 4/6 (66.7) 24/65 (36.9) 0.204
*Duration of symptom (month) 36.0 (3.5, 55.5) 3.0 (1.0, 6.0) 0.127
*CRP (mg/dL) 0.48 (0.31, 1.87) 0.45 (0.18, 1.31) 0.407
ANA (positive) 3/6 (50.0) 15/53 (28.3) 0.357
RF (positive) 1/4 (25.0) 10/55 (18.2) 0.572
Outcome 0.303
Alive 7/9 (77.8) 66/86 (76.7)
Death 1/9 (11.1) 2/86 (2.3)
Follow-up loss 1/9 (11.1) 18/86 (20.9)
Note: Values in parentheses are percentages
F:M female:male, FVC forced vital capacity, % pred percentage of the predicted value, FEV1 forced expiratory volume, DLCO diffusing capacity of the lung for carbon
monoxide, PaO2 arterial oxygen tension, CRP C-reactive protein, ANA antinuclear antibody, RF rheumatoid factor
Note: data are expressed as the median with interquartile range or number with proportion (%)
*CRP showed non-normal distribution in the no treatment group
*Resting PaO2 mm Hg, duration of symptoms, and CRP showed a non-normal distribution in the treatment group
Table 3 Comparison between initial and 1-year follow-up lung function according to antinuclear antibody (ANA) positivity
ANA negative (n = 41) ANA positive (n = 18)
Initial Follow-up p-value Initial Follow-up p-value
FVC (%) 72.1 ± 20.6 83.2 ± 15.5 0.008 68.6 ± 19.5 76.4 ± 18.1 0.102
FEV1 (%) 80.1 ± 23.7 91.4 ± 19.7 0.005 75.4 ± 19.0 83.7 ± 19.1 0.091
DLco (%) 68.7 ± 24.9 80.8 ± 26.0 <0.001 62.9 ± 21.1 64.9 ± 23.4 0.568
FVC forced vital capacity, % pred percentage of the predicted value, FEV1 forced expiratory volume, DLCO diffusing capacity of the lung for carbon monoxide,
ANA antinuclear antibody
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characteristics of NSIP can be found in these diseases
[15–18]. Due to the complexity of the diagnosis and low
prevalence of NSIP, the factors predicting the response
to treatment or the therapeutic effect are not well
known [1, 6].
In the treatment group, lung function significantly im-
proved after 1 year compared to the initial assessment;
FVC (%) increased by 10.0%, FEV1 by 9.8%, and DLCO
by 8.4%. Park et al. [9] showed that the change in FVC
(%) occurred according to histopathological type and the
survival outcome; treatment response was better in
cellular-type, and there was a 25% increase in FVC (%)
in the cellular-type/survivor group after 1 year. However,
there was no improvement in FVC (%) in the fibrotic-
type/non-survivor group. Additionally, in their study, the
initial mean FVC (%) was 63.6 ± 14.6, which was lower
than what we observed. Xu et al. [8] also investigated
the change in PFT results, but there was no significant
improvement between the initial and follow-up lung
function, possibly due to the non-fixed follow-up dur-
ation in their study. From our results, in the early stages
of iNSIP, a clinician could anticipate that treatment
Table 4 Comparison of clinical characteristics between the
response group and non-response group
Response
group (n = 42)
Non-response
group (n = 44)
p-value
*Age (year) 55.5 ± 11.3 55.8 ± 9.7 0.895
F: M 28 (66.7): 14
(33.3)
31 (70.5): 13
(29.5)
0.705
Follow-up duration (month) 36.6 ± 14.1 28.6 ± 12.2 0.006
Pulmonary function test
FVC (%) 63.6 ± 17.6 79.9 ± 18.4 <0.001
FEV1 (%) 71.7 ± 20.8 88.6 ± 19.9 <0.001
DLco (%) 56.9 ± 19.0 70.5 ± 25.0 0.008
Resting PaO2 mm Hg 81.4 ± 17.0 92.5 ± 11.0 0.004
Smoking status 0.022
Never smoker 30/40 (75.0) 32/43 (74.4)
Ex-smoker 10/40 (25.0) 5/43 (11.6)
current smoker . 6/43 (14.0)
Smoking amount (Pys) 26.5 ± 17.2 32.4 ± 15.1 0.415
Initial symptom
Dyspnea of exertion 28/35 (80.0) 30/36 (83.3) 0.717
Cough 26/36 (72.2) 23/36 (63.9) 0.448
Sputum 13/33 (39.4) 11/32 (34.4) 0.675
*Duration of Symptom
(month)
3.4 ± 4.4 7.1 ± 9.3 0.038
*CRP (mg/dL) 1.97 ± 5.01 1.19 ± 2.19 0.416
ANA (positive) 3/25 (12.0) 12/28 (42.9) 0.013
RF (positive) 2/25 (8.0) 8/30 (26.7) 0.092
Outcome 0.105
Alive 30/42 (71.4) 36/44 (81.8)
Death . 2/44 (4.5)
Follow-up loss 12/42 (28.6) 6/44 (13.6)
Note: Values in parentheses are percentages
F:M female:male, FVC forced vital capacity, % pred percentage of the predicted
value, FEV1 forced expiratory volume, DLCO diffusing capacity of the lung for
carbon monoxide, PaO2 arterial oxygen tension, CRP C-reactive protein,
ANA antinuclear antibody, RF rheumatoid factor
*Duration of symptoms, and CRP showed a non-normal distribution in the
response group
*Age, duration of symptoms, and CRP showed a non-normal distribution in the
non-response group
Fig. 2 Changes in lung function over time between the response
group and non-response group. a Change in functional vital capacity
(FVC) (%) over time between the two groups (p < 0.001, Mean ±
standard error (SE), b Change in the diffusing capacity of the lung
for carbon monoxide (DLCO) (%) over time between the two groups
(p = 0.002, Mean ± SE)
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would result in a 10% improvement in FVC (%) after
1 year. This information could help physicians predict
the clinical course of patients with iNSIP, and plan
adequate treatment modality.
Lee et al. [10] reported similar results to our study,
showing that the presence of ANA was significantly re-
lated with disease progression and a poor response to
corticosteroids. They suggested that sero-positivity of
ANA could be an early manifestation of systemic dis-
eases associated with a poor outcome of NSIP. Xu et al.
[19] also showed that systemic autoimmune disease was
significantly associated with increased mortality in NSIP
patients (p = 0.023). Felicio et al. [20] reported a higher
production of collagen and elastic fibers in NSIP with
collagen vascular disease than in iNSIP; in a cohort of
41 NSIP patients, an increase in elastic fibers >1.5% was
a significant risk factor for poor outcome (p = 0.01). In
this study, the response group showed a lower pro-
portion of ANA positivity than the non-response
group (p = 0.013). Furthermore, negative ANA was
associated with a significant improvement in lung
function after 1 year.
Sawata et al. [21] studied the influence of smoking in 31
NSIP patients over 2 years. They showed that the smoking
group had a significantly worse outcome than the non-
smoking group; smoking was significantly related with a
lower %DLCO/alveolar ventilation (DLCO/VA) in both
iNSIP (p = 0.009) and CTD-NSIP (p = 0.044), and progres-
sion free survival was worse in the smoker group (p =
0.0489). Furthermore, they showed that exacerbation was
common in a heavy smoker. Similarly, in our study, the
non-response group had a relatively higher total smoking
patient number than the response group, and current
smokers were only observed in the non-response group
(Table 4, p = 0.022). Marten et al. [22] suggested that em-
physema is higher in smokers with NSIP; therefore,
cigarette smoking could be a pathogenic factor in a subset
of NSIP patients. Thus, we presumed that smoking is re-
lated with NSIP pathogenesis, and could provoke a poor
response to corticosteroids, causing a worse outcome.
To assess the severity in the study population, we cal-
culated the ILD-GAP score, which is a clinical prognosis
prediction model using age, gender, and two lung func-
tion parameters (FVC (%), DLCO (%)) [23, 24]. Although
the initial PFT results were lower in the response group,
the majority of patients in this study had ILD-GAP stage
I (96.6%, data not shown). Moreover, a relatively longer
duration of respiratory symptoms was a risk factor for
poor response to corticosteroids (Table 5). This could
mean that early treatment with corticosteroids and/or
immunosuppressants might be more beneficial in the
early stage of iNSIP, especially in ILD-GAP stage I
patients. The physician should consider treatment of
idiopathic NSIP in patients with respiratory symptoms,
even if the severity of iNSIP is low.
There are some limitations to this study. First, it had a
patient selection bias. This study was performed
retrospectively and patients with ILD were enrolled in each
hospital without a specific visit protocol. Therefore, 1-year
follow-up PFT results exist in only 95 patients.
Additionally, there have been major advances in the
conceptualization of NSIP in recent years. In particular, it
is currently speculated that iNSIP could be a type of auto-
immune disease that is limited to the lungs or the respira-
tory manifestation of undifferentiated CTD [5, 18, 25].
Initially, we only enrolled patients without autoimmune
disease and nine patients who developed CTD were
excluded from this study. Nevertheless, there could be
differences between this study population’s patients and
currently diagnosed NSIP patients. Second, the NSIP sub-
type (cellular type, fibrotic type, or mixed) was not exam-
ined in this study. Previous studies showed that fibrotic
NSIP was related with a poor prognosis and more
frequent hospitalization [9, 11, 26]. If the subtype was in-
vestigated, it would be more informative. Third, the initial
dose of corticosteroids or immunosuppressive agents was
not examined. Lee et al. [10] reported that a low cortico-
steroid dose was significantly related with relapse, which
could mean that the dose of corticosteroids administered
could affect the response to treatment.
Conclusion
Our study showed that corticosteroid and/or immunosup-
pressant therapy was effective in iNSIP, resulting in an im-
provement in lung function after 1 year. Corticosteroid-
based treatment was especially effective in iNSIP patients
who showed sero-negativity for ANA and those who had
a shorter duration of respiratory symptoms. These
findings suggest that early treatment with corticoste-
roids and/or immunosuppressants could be therapeut-
ically beneficial in iNSIP patients, even if the disease
is at an early stage. Further prospective, large, and
well-designed studies are needed to confirm the factors af-
fecting treatment effect.
Table 5 Analysis of risk factors that affect treatment response
by logistic regression
Variables Odds ratio 95% CI p-value
Age 1.026 0.913 to 1.152 0.665
Gender (M/F) 0.554 0.103 to 2.997 0.493
Duration of symptoms at
diagnosis (Month)
1.385 1.058 to 1.813 0.018
FVC (% pred) at diagnosis 1.052 0.979 to 1.131 0.170
DLCO (% pred) at diagnosis 0.995 0.951 to 1.042 0.838
PaO2 at diagnosis 1.014 0.954 to 1.079 0.645
M/F male/female, FVC forced vital capacity, % pred percentage of the
predicted value, DLCO diffusing capacity of the lung for carbon monoxide,
PaO2 arterial oxygen tension, CI confidence interval
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